Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE

US Bancorp DE grew its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 147.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,971 shares of the biotechnology company's stock after purchasing an additional 7,137 shares during the period. US Bancorp DE's holdings in Blueprint Medicines were worth $1,107,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Blueprint Medicines by 3.2% in the 1st quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company's stock valued at $598,564,000 after purchasing an additional 195,007 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Blueprint Medicines by 15.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company's stock valued at $592,954,000 after buying an additional 821,868 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Blueprint Medicines by 4.2% during the 2nd quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company's stock valued at $86,519,000 after buying an additional 32,600 shares during the period. Millennium Management LLC lifted its position in Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company's stock worth $67,646,000 after acquiring an additional 529,566 shares in the last quarter. Finally, Hood River Capital Management LLC boosted its holdings in Blueprint Medicines by 7.0% in the 2nd quarter. Hood River Capital Management LLC now owns 502,820 shares of the biotechnology company's stock worth $54,194,000 after acquiring an additional 32,694 shares during the period.

Insiders Place Their Bets

In other news, insider Fouad Namouni sold 3,633 shares of the business's stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares of the company's stock, valued at approximately $6,169,332.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.21% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of Blueprint Medicines from $75.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, July 29th. UBS Group initiated coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective on the stock. Wells Fargo & Company lowered their target price on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research note on Thursday, October 31st. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday. Finally, Baird R W raised Blueprint Medicines to a "strong-buy" rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $120.39.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC traded down $0.56 during trading on Friday, reaching $100.83. 625,068 shares of the company's stock traded hands, compared to its average volume of 708,823. The stock has a market capitalization of $6.41 billion, a P/E ratio of -47.79 and a beta of 0.59. Blueprint Medicines Co. has a 12 month low of $56.74 and a 12 month high of $121.90. The company has a 50 day moving average of $89.21 and a 200-day moving average of $98.79. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business's revenue was up 126.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.20) earnings per share. On average, equities analysts expect that Blueprint Medicines Co. will post -3.61 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.